Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KUR-101
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Kures' flagship product, KUR-101, is a derivative of mitragynine, the major active alkaloid of the kratom plant. KUR-101 will join ATAI's pipeline of ground-breaking mental health interventions such as arketamine and psilocybin.
Product Name : KUR-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 07, 2020
Lead Product(s) : KUR-101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Acquisition